Purpose. Original articles and abstracts published between January 1991 and January 1997 were selected according to specified criteria and reviewed to provide answers to five interesting questions about the systemic treatment of metastatic osteosarcoma.
Introduction
With modem intensive multi-agent chemotherapy, 5 -year overall survival (OS) figures for nonmetastatic extremity osteosarcoma of children and young adults have improved and are in the range 40-80%. Unfortunately, between 15 and 20% of patients with osteosarcoma will present with clinically detectable metastases, a proportion that has increased with sophisticated methods of detection such as computed tomography (CT) or magnetic resonance imaging (MRI) . As determined by measurable clinical response, chemotherapy so far has produced rather unimpressive results in metastatic osteosarcoma. 2 Early data showed overall response rates for single agents such as doxorubicin (DOX), cisplatinum (DDP), high-dose methotrexate (HDMTX) and ifosfamide (IFOS) of between 15 and 25%, with even lower response rates, 8- 15/% for agents such as bleomycin, cyclophosphamide, actinomycin D (BCD), dacarbazine, melphalan and mitomycin C.
The serendipitous discovery that high rates of necrosis could occur in tumors of patients receiving neo-adjuvant chemotherapy while awaiting manufacture of prostheses, 3 and the establishment of a clear link between a good pathological response (> 90% necrosis) in the primary and a good out- 
Data identification
A computerized search of Medline and Cancerlit databases for the years January 1991-January 1997 was performed specifying the key words 'osteosarcoma' and 'chemotherapy', and limiting the search to the English language. This was supplemented by papers in the author's files and scrutiny of reference lists of previous reviews and key articles.
Data selection
Publications were selected for review if they met the following criteria:
(1) patients had histologically confirmed osteosarcoma; (2) (Table 2 ). In three of the four studies in which a prognostic factor analysis was performed, complete resection of metastases was independently correlated with improved survival.
In the multi-institutional study (MIOS), patients relapsing after surgery alone had a significantly longer interval to further disease progression (p<0.01) and improved survival after relapse (p-0.01) compared with those relapsing after treatment with immediate chemotherapy. 
